nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00131014,Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies,,Recruiting,Observational,"Non-Hodgkin's Lymphoma; Hodgkin's Disease; Leukemia, Lymphocytic, Chronic; Lymphoproliferative Disorders",,,Dana-Farber Cancer Institute,,1500,2004-08-09,2033-01-05,United States,No,https://clinicaltrials.gov/study/NCT00131014
NCT01137643,Tissue Procurement For Hematolymphoid Conditions,,Recruiting,Observational,Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm,biologic sample preservation procedure; cytology specimen collection procedure,,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),15000,2009-07-05,2040-07-05,United States,No,https://clinicaltrials.gov/study/NCT01137643
NCT01890486,"The Prospective Collection, Storage and Reporting of Data on Patients",,Recruiting,Observational,Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma; Germ Cell Neoplasms; Myelodysplastic Syndromes; Chronic Lymphocytic Leukemia; Immunodeficiency Diseases,,,Wake Forest University Health Sciences,,2000,2001-05-21,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT01890486
NCT03072927,MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study,,Recruiting,Observational,Lumbar Spinal Stenosis,MILD; Interspinous Process Decompression,,Stryker Instruments,,8000,2017-03-10,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT03072927
NCT03219450,"A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.",Phase 1,Recruiting,Interventional,Lymphocytic Leukemia,NeoVax; Cyclophosphamide; Pembrolizumab,,Dana-Farber Cancer Institute,"Oncovir, Inc.; BioNTech SE; Merck Sharp & Dohme LLC",15,2021-08-18,2028-03-31,United States,No,https://clinicaltrials.gov/study/NCT03219450
NCT03263572,Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),Phase 2,Recruiting,Interventional,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia; t(9;22)",Blinatumomab; Cytarabine; Methotrexate; Ponatinib,,M.D. Anderson Cancer Center,National Cancer Institute (NCI); Amgen; Takeda,90,2017-11-29,2027-11-30,United States,No,https://clinicaltrials.gov/study/NCT03263572
NCT03331198,"An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)",Phase 1/Phase 2,Recruiting,Interventional,"Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic",JCAR017 (lisocabtagene maraleucel); JCAR017 (lisocabtagene maraleucel) + ibrutinib; JCAR017 (lisocabtagene maraleucel) + venetoclax,,"Juno Therapeutics, a Subsidiary of Celgene",,320,2017-11-27,2027-11-26,Canada; United States,No,https://clinicaltrials.gov/study/NCT03331198
NCT03494569,Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome,Phase 1,Recruiting,Interventional,Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia; Acute Myeloid Leukemia in Remission; Hematopoietic Cell Transplantation Recipient; Minimal Residual Disease; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia,Fludarabine; Laboratory Biomarker Analysis; Melphalan; Total Marrow Irradiation,,City of Hope Medical Center,National Cancer Institute (NCI),36,2018-07-06,2026-09-08,United States,No,https://clinicaltrials.gov/study/NCT03494569
NCT03802695,"A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies",Phase 1,Recruiting,Interventional,Acute Myeloid Leukemia; Myelodysplastic Syndromes; Mixed Phenotype Acute Leukemia; Acute Lymphoblastic Leukemia,OrcaGraft (Orca-Q),,"Orca Biosystems, Inc.",,300,2019-04-08,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT03802695
NCT04169737,A Randomized Phase II Study of Acalabrutinib (ACA) + Venetoclax (VEN) +/- Early Obinutuzumab (OBIN) for Patients With Chronic Lymphocytic Leukemia (CLL),Phase 2,Recruiting,Interventional,Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma,Acalabrutinib; Obinutuzumab; Venetoclax,,M.D. Anderson Cancer Center,"National Cancer Institute (NCI); AstraZeneca; Genentech, Inc.",168,2020-07-29,2026-07-09,United States,No,https://clinicaltrials.gov/study/NCT04169737
NCT04195633,Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen,Phase 2,Recruiting,Interventional,"Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Adult Diffuse Large Cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Chronic Myeloid Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; Hodgkin Lymphoma; Lymphoblastic Lymphoma; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome; Prolymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Follicular Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma",Allogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Filgrastim; Fludarabine; Mycophenolate Mofetil; Mycophenolate Sodium; Total-Body Irradiation; Treosulfan; Bone Marrow Aspiration; Bone Marrow Biopsy; Echocardiography Test; Biospecimen Collection; Computed Tomography; Positron Emission Tomography,,Fred Hutchinson Cancer Center,medac GmbH,60,2021-01-25,2028-01-10,United States,No,https://clinicaltrials.gov/study/NCT04195633
NCT04260022,"A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)",Phase 1,Recruiting,Interventional,"Leukemia, Myeloid, Chronic; Myeloid Leukemia; Chronic Myeloid Leukemia; Philadelphia Positive Acute Lymphoblastic Leukemia; B Cell Precursor Type Acute Leukemia",Ascentage Pharma HQP1351 bioavailable inhibitor; Blinatumomab,,Ascentage Pharma Group Inc.,,242,2020-01-09,2030-03-31,Canada; United States,No,https://clinicaltrials.gov/study/NCT04260022
NCT04329728,"An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)",Phase 1/Phase 2,Recruiting,Interventional,Lymphoid Malignancies,AVM0703,,AVM Biotechnology Inc,"Medpace, Inc.",144,2020-11-06,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT04329728
NCT04679012,Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation,Phase 2,Recruiting,Interventional,Richter Syndrome; Chronic Lymphocytic Leukemia,Polatuzumab Vedotin; Rituximab; Etoposide; Prednisone; Cyclophosphamide; Hydroxydaunomycin,,Weill Medical College of Cornell University,"Genentech, Inc.",20,2021-09-24,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04679012
NCT04690595,A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,Phase 1,Recruiting,Interventional,Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,BAFFR-CAR T cells,,"PeproMene Bio, Inc.",City of Hope Medical Center,24,2021-05-18,2027-11-18,United States,No,https://clinicaltrials.gov/study/NCT04690595
NCT04747912,A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO),Phase 2,Recruiting,Interventional,Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia; ph+ Acute Lymphoblastic Leukemia,Inotuzumab ozogamicin; Dasatinib; Dexamethasone; Methotrexate; Vincristine; Ponatinib; Methotrexate for Injection; Allogenic Stem Cell Transplantation,,University of Chicago,,25,2021-03-02,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT04747912
NCT04830137,"A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies",Phase 1,Recruiting,Interventional,Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Waldenstrom Macroglobulinemia (WM); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); Primary Central Nervous System Lymphoma (PCNSL),NX-2127,,"Nurix Therapeutics, Inc.",,248,2021-05-05,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT04830137
NCT04844528,Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC),Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Non-melanoma Skin Cancer (NMSC),Nicotinamide; Placebo,,University of Utah,Huntsman Cancer Institute,86,2022-02-25,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT04844528
NCT05031897,A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity Conditioning,Phase 2,Recruiting,Interventional,"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Adult T-Cell Leukemia/Lymphoma; Aplastic Anemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; Essential Thrombocythemia; Hematopoietic and Lymphatic System Neoplasm; Hodgkin Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myelofibrosis; Myeloid Neoplasm; Non-Hodgkin Lymphoma; Polycythemia Vera; Small Lymphocytic Lymphoma",Fludarabine; Total-Body Irradiation; Donor Lymphocyte Infusion; Cyclophosphamide; Tacrolimus; Mycophenolate Mofetil; Hematopoietic Cell Transplantation; Melphalan; Bone Marrow Aspiration and Biopsy; Diagnostic Imaging; Biospecimen Collection,,Thomas Jefferson University,,63,2021-10-25,2032-04-05,United States,No,https://clinicaltrials.gov/study/NCT05031897
NCT05131022,"A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies",Phase 1,Recruiting,Interventional,Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Waldenstrom Macroglobulinemia (WM); Primary Central Nervous System Lymphoma (PCNSL); Secondary Central Nervous System Lymphoma (SCNSL),NX-5948,,"Nurix Therapeutics, Inc.",,572,2022-04-13,2028-01-05,France; Italy; Netherlands; Poland; Spain; Switzerland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05131022
NCT05170399,Vaccine Responses in Patients With B Cell Malignancies,Phase 4,Recruiting,Interventional,Lymphoma,"Fluzone; Shingrix; Flucelvax; Afluria; PREVNAR 13; Heplisav -B; Pfizer-COVID-19 Vaccine; FluLaval; Fluarix; PNEUMOVAX 23; PREVNAR 20; AREXVY, ABRYSVO",,"National Heart, Lung, and Blood Institute (NHLBI)",,500,2022-09-14,2026-08-16,United States,No,https://clinicaltrials.gov/study/NCT05170399
NCT05240885,Metabolic and Functional Consequences of Aging in Health and Disease,,Recruiting,Observational,Aging,Stable tracer infusion in a postabsorptive state,,Texas A&M University,,100,2022-03-04,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05240885
NCT05254743,"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)",Phase 3,Recruiting,Interventional,"Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma",Pirtobrutinib; Ibrutinib,,"Loxo Oncology, Inc.",,662,2022-07-22,2028-01-05,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Hungary; Israel; Italy; Japan; New Zealand; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05254743
NCT05279300,"A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Advanced Lymphoma,CS5001; Rituximab; Gemcitabine; Oxaliplatin; Lenalidomide; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone,,CStone Pharmaceuticals,,480,2022-03-28,2027-12-31,Australia; China; United States,No,https://clinicaltrials.gov/study/NCT05279300
NCT05336812,Prospective Randomized Phase II Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL,Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Acalabrutinib; Obinutuzumab; Venetoclax,,Ohio State University Comprehensive Cancer Center,,52,2022-09-13,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT05336812
NCT05400733,Prandial Metabolic Phenotype in Adults,Not Applicable,Recruiting,Interventional,Protein Metabolism,Total Amino Acids; Essential Amino Acids; Essential Amino Acids + Hydroxy-methylbutyric acid (HMB); Essential Amino Acids + Leucine; Essential Amino Acids High; Placebo Water,,Texas A&M University,,50,2022-06-24,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05400733
NCT05544019,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies",Phase 1,Recruiting,Interventional,"Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma",SGR-1505,,"Schrödinger, Inc.",,52,2023-04-10,2026-03-05,France; Italy; Moldova; Poland; Romania; Spain; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05544019
NCT05602363,A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma,Phase 1,Recruiting,Interventional,B-cell Malignancy; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Non-Hodgkin Lymphoma,Docirbrutinib,,"Carna Biosciences, Inc.",,120,2023-08-01,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT05602363
NCT05645107,"A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment Compared to Placebo Plus Standard Medical Treatment to Prevent Infections in Patients With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma",Phase 3,Recruiting,Interventional,Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia; Multiple Myleoma; Non-Hodgkin Lymphoma,Xembify; Placebo,,Grifols Therapeutics LLC,,386,2022-12-26,2026-06-05,Bosnia and Herzegovina; Bulgaria; Croatia; Hungary; Poland; Romania; Serbia; United States,No,https://clinicaltrials.gov/study/NCT05645107
NCT05672355,Randomized Observer-Blinded Phase 2 Trial of COVID-19 Booster With GEO-CM04S1 or mRNA Vaccine in Patients With Chronic Lymphocytic Leukemia,Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; COVID-19 Infection,Biospecimen Collection; mRNA COVID-19 Vaccine; Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1,,City of Hope Medical Center,National Cancer Institute (NCI),80,2023-08-01,2026-01-12,United States,No,https://clinicaltrials.gov/study/NCT05672355
NCT05702853,A Phase 1b Dose Escalation Study of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers in Adult Patients With Relapsed or Refractory CD19 B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Phase 1/Phase 2,Recruiting,Interventional,B-cell Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia,Cyclophosphamide injection; Fludarabine Injection; CD19-CD34t metabolically programmed CAR transduced T-cells,,Medical University of South Carolina,,27,2023-11-06,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT05702853
NCT05724121,Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax,,Recruiting,Observational,Chronic Lymphocytic Leukemia (CLL); Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia; Mantle Cell Lymphoma; Sudden Cardiac Death; Cardiac Arrhythmias; Hematologic Malignancies,,,"National Heart, Lung, and Blood Institute (NHLBI)",,135,2023-03-01,2027-04-08,United States,No,https://clinicaltrials.gov/study/NCT05724121
NCT05780034,"A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Malignancy Activity of AC676 in Patients With Relapsed/Refractory B-cell Malignancies",Phase 1,Recruiting,Interventional,Relapsed/Refractory B-cell Malignancies,AC676,,Accutar Biotechnology Inc,,60,2023-06-20,2026-05-31,United States,No,https://clinicaltrials.gov/study/NCT05780034
NCT05805605,Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases,Phase 2,Recruiting,Interventional,"Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Biphenotypic Acute Leukemia; Undifferentiated Leukemia; Prolymphocytic Leukemia; Chronic Myelogenous Leukemia; Plasma Cell Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid; Myelodysplastic Syndrome With Excess Blasts-1; Burkitt Lymphoma; Relapsed T-Cell Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Follicular Lymphoma; Myeloproliferative Neoplasm; Myelofibrosis",Peripheral Blood Stem Cell Transplant; Allopurinol 300 MG; Fludarabine; Cyclophosphamide; Bone Marrow Cell Transplant; Total Body Irradiation; Sirolimus Pill; Mycophenolate Mofetil,,"Masonic Cancer Center, University of Minnesota",,56,2023-05-01,2028-10-22,United States,No,https://clinicaltrials.gov/study/NCT05805605
NCT05873712,A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome,Phase 2,Recruiting,Interventional,Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Transformed,Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Fludarabine; Leukapheresis; Lisocabtagene Maraleucel; Lymph Node Biopsy; Positron Emission Tomography; Zanubrutinib,,Aseel Alsouqi,BeOne Medicines,24,2023-07-28,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05873712
NCT05879133,HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia,Not Applicable,Recruiting,Interventional,Chronic Lymphocytic Leukemia,Questionnaires; Fit Bit,,M.D. Anderson Cancer Center,CLL Global Research Foundation,30,2023-05-17,2027-07-03,United States,No,https://clinicaltrials.gov/study/NCT05879133
NCT05899543,Exploring Patient Experiences of Individuals Joining Chronic Lymphocytic Leukemia Clinical Trials,,Not yet recruiting,Observational,Chronic Lymphocytic Leukemia,,,Power Life Sciences Inc.,,500,2024-07-05,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT05899543
NCT05959434,Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and Co-Occurring PTSD: A Randomized Clinical Trial,Phase 2,Recruiting,Interventional,Posttraumatic Stress Disorder; Alcohol Use Disorder,Cognitive Processing Therapy + Relapse Prevention; Relapse Prevention,,Texas A&M University,Medical University of South Carolina; National Institute on Alcohol Abuse and Alcoholism (NIAAA),200,2024-04-01,2028-07-31,United States,No,https://clinicaltrials.gov/study/NCT05959434
NCT05963074,Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia,Phase 2,Recruiting,Interventional,"Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma",Ibrutinib; Venetoclax,,"Janssen Research & Development, LLC",Pharmacyclics LLC.,320,2024-05-30,2029-03-19,Canada; Czechia; France; Hungary; Italy; Poland; Spain; United States,No,https://clinicaltrials.gov/study/NCT05963074
NCT06059391,Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant,Phase 2,Recruiting,Interventional,"Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Hodgkin Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma",Allogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Transplantation Conditioning Regimen; Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Pheresis; Placebo Administration; Stem Cell Mobilization Therapy,,City of Hope Medical Center,National Cancer Institute (NCI),216,2024-07-12,2029-01-01,United States,No,https://clinicaltrials.gov/study/NCT06059391
NCT06102330,Multicenter HomeVENT: Home Values and Experiences Navigation Track,Not Applicable,Recruiting,Interventional,Pediatric ALL; Respiratory Insufficiency; Communication,HomeVENT decision support tool,,Johns Hopkins University,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),600,2024-02-06,2030-12-05,United States,No,https://clinicaltrials.gov/study/NCT06102330
NCT06136559,"A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)",Phase 3,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Nemtabrutinib; Ibrutinib; Acalabrutinib,,Merck Sharp & Dohme LLC,,1200,2023-12-13,2032-09-07,Australia; Belgium; Brazil; Canada; Chile; China; Colombia; Czechia; Denmark; Germany; Greece; Hong Kong; Israel; Japan; Malaysia; Mexico; New Zealand; Norway; Peru; Poland; Portugal; South Africa; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06136559
NCT06207123,"A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBL",Phase 1/Phase 2,Recruiting,Interventional,Acute Leukemia; Lymphoblastic Leukemia; Lymphoblastic Lymphoma,LP-118; Ponatinib; Vincristine; Dexamethasone; Methotrexate,,University of Chicago,,15,2024-09-13,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT06207123
NCT06211413,A Prospective Longitudinal Cohort Study of the Incidence of Hypertension and Arrhythmias in Patients Treated with Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia Using Wearable Technology,,Enrolling by invitation,Observational,Chronic Lymphocytic Leukemia; Atrial Fibrillation; Hypertension; Cardiotoxicity,no intervention,,Abramson Cancer Center at Penn Medicine,,50,2024-02-07,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT06211413
NCT06227026,Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies,Phase 1,Recruiting,Interventional,Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma,Anti-CD19 CAR-T cells,,University of Utah,,10,2024-02-20,2027-01-15,United States,No,https://clinicaltrials.gov/study/NCT06227026
NCT06466122,Phase 2 Study of Combination Pirtobrutinib (LOXO-305) and Venetoclax in CLL Patients With Resistance to Covalent BTKi,Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Pirtobrutinib; Venetoclax,,Kerry Rogers,,30,2024-11-07,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT06466122
NCT06536452,Hematopoiesis in Monoclonal B Cell Lymphocytosis (MBL) and B-Chronic Lymphocytic Leukemia (CLL) Versus Healthy Age-Matched Control Subjects,,Recruiting,Observational,Chronic Lymphocytic Leukemia; Monoclonal B-Cell Lymphocytosis,Non-Interventional Study,,Mayo Clinic,,50,2016-11-18,2026-11-18,United States,No,https://clinicaltrials.gov/study/NCT06536452
NCT06575296,A Phase I Study of SNDX 5613 (Revumenib) as Post-Transplant Maintenance After Allogeneic Hematopoietic Cell Transplant in Patients With KMT2A-Rearranged or NPM1-Mutated Acute Leukemia,Phase 1,Recruiting,Interventional,Acute Leukemia; Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Childhood Acute Leukemia; Childhood Acute Leukemia of Ambiguous Lineage; Childhood Acute Lymphoblastic Leukemia; Childhood Acute Myeloid Leukemia,Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Echocardiography; Electronic Health Record Review; Quality-of-Life Assessment; Questionnaire Administration; Revumenib,,City of Hope Medical Center,National Cancer Institute (NCI),27,2024-12-06,2028-04-29,United States,No,https://clinicaltrials.gov/study/NCT06575296
NCT06588478,"A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor",Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma,Pirtobrutinib,,"Loxo Oncology, Inc.",Eli Lilly and Company,249,2025-01-03,2028-12-05,Australia; Belgium; Canada; Czechia; Denmark; France; Germany; Greece; Hungary; Italy; Poland; Romania; Slovakia; South Korea; Spain; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06588478
NCT06628349,Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein,Not Applicable,Recruiting,Interventional,Protein Metabolism,Whey Protein Isolate 90%; Soy Protein Isolate (90% Protein); Organic Pea Protein Isolate; Placebo (Water),,Texas A&M University,,100,2024-02-01,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06628349
NCT06636175,Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B,Early Phase 1,Recruiting,Interventional,Multiple Myeloma; Low-Grade Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Lymphoplasmacytic Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia,64Cu-LLP2A; PET/CT,,Washington University School of Medicine,National Cancer Institute (NCI),42,2025-02-26,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT06636175
NCT06676033,Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome,Phase 1,Recruiting,Interventional,"Leukemia, Chronic Lymphocytic; Richter Syndrome",epcoritamab,,"National Heart, Lung, and Blood Institute (NHLBI)",,30,2025-07-18,2027-07-01,United States,No,https://clinicaltrials.gov/study/NCT06676033
NCT06680661,ABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis,Phase 2,Recruiting,Interventional,Acute Myelogenous Leukemia; Acute Lymphatic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myelodysplastic Syndrome Other; Chronic Myelomonocytic Leukemia; Lymphoma; Hodgkin Lymphoma,Cyclophosphamide; Fludarabine; Thiotepa; Total Body Irradiation; Double Umbilical Cord Transplant; Tacrolimus; Mycophenolate Mofetil; Abatacept,,Leland Metheny,,20,2025-02-25,2028-10-31,United States,No,https://clinicaltrials.gov/study/NCT06680661
NCT06712810,"MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor",Phase 1,Recruiting,Interventional,"Hematopoietic and Lymphatic System Neoplasm; Histiocytic Sarcoma; Malignant Histiocytosis; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Follicular Lymphoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelofibrosis; Recurrent Small Lymphocytic Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Erdheim-Chester Disease; Refractory Follicular Lymphoma; Refractory Langerhans Cell Histiocytosis; Refractory Lymphoplasmacytic Lymphoma; Refractory Myelodysplastic Syndrome; Refractory Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Refractory Waldenstrom Macroglobulinemia; Rosai-Dorfman-Destombes Disease; Primary Central Nervous System Lymphoma; Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm; Recurrent Erdheim-Chester Disease; Recurrent Fibroblastic Reticular Cell Sarcoma; Recurrent Histiocytic Sarcoma; Recurrent Interdigitating Dendritic Cell Sarcoma; Recurrent Rosai-Dorfman-Destombes Disease; Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm; Refractory Fibroblastic Reticular Cell Sarcoma; Refractory Histiocytic Sarcoma; Refractory Interdigitating Dendritic Cell Sarcoma; Refractory Rosai-Dorfman-Destombes Disease",Axl/Mer/CSF1R Inhibitor Q702; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Survey Administration,,Mayo Clinic,,46,2025-08-27,2030-09-15,United States,No,https://clinicaltrials.gov/study/NCT06712810
NCT06735664,A Phase I Study of Covalent BTK Inhibitor Zanubrutinib in Combination With a CD3-CD20 Bispecific Antibody Odronextamab in Patients With Richter's Transformation,Phase 1,Recruiting,Interventional,Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma,Biopsy; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Echocardiography; Multigated Acquisition Scan; Odronextamab; Positron Emission Tomography; Ultrasound Imaging; Zanubrutinib,,City of Hope Medical Center,National Cancer Institute (NCI),23,2025-08-14,2027-12-13,United States,No,https://clinicaltrials.gov/study/NCT06735664
NCT06788639,Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Post-Marketing Setting,,Recruiting,Observational,Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL),Lisocabtagene maraleucel,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",,300,2025-02-04,2044-06-30,United States,No,https://clinicaltrials.gov/study/NCT06788639
NCT06823167,A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies,Phase 1,Recruiting,Interventional,Solid Malignancies; Hematologic Malignancies,IM-1021,,"Immunome, Inc.",,117,2025-02-26,2029-02-05,United States,No,https://clinicaltrials.gov/study/NCT06823167
NCT06839053,"Escalated Inpatient Ramp-Up of Sonrotoclax in Patients With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Mantle Cell Lymphoma (MCL) (SONIC Study)",Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Mantle Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Mantle Cell Lymphoma; Refractory Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma,Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Gastrointestinal Endoscopy; Rituximab; Sonrotoclax; Zanubrutinib,,Fred Hutchinson Cancer Center,BeOne Medicines,20,2025-06-02,2032-07-01,United States,No,https://clinicaltrials.gov/study/NCT06839053
NCT06846671,"A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors",Phase 3,Recruiting,Interventional,CLL; Chronic Lymphocytic Leukemia,BGB-16673; Bendamustine; Idelalisib; Rituximab; Venetoclax,,BeOne Medicines,,250,2025-04-10,2030-02-14,Argentina; Australia; Brazil; Czechia; Germany; Italy; Japan; Poland; South Korea; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06846671
NCT06863402,Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study,Phase 2,Recruiting,Interventional,Richter Syndrome; Diffuse Large B-Cell Lymphoma; Chronic Lymphocytic Leukemia,Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Echocardiography; Multigated Acquisition Scan; Nemtabrutinib; Pembrolizumab; Positron Emission Tomography; Questionnaire Administration,,Roswell Park Cancer Institute,,32,2026-02-15,2030-04-01,United States,No,https://clinicaltrials.gov/study/NCT06863402
NCT06876662,Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma,Phase 4,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma,Pirtobrutinib,,Eli Lilly and Company,,279,2025-05-20,2032-12-05,Australia; France; Italy; Japan; Poland; South Korea; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06876662
NCT06972264,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia",Phase 3,Recruiting,Interventional,Androgenetic Alopecia; AGA; Male Pattern Baldness,VDPHL01; Placebo,,"Veradermics, Inc.",,480,2025-03-11,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT06972264
NCT07030400,Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,,Recruiting,Observational,Small Lymphocytic Lymphoma (SLL); Chronic Lymphocytic Leukemia (CLL),Bruton's tyrosine kinase inhibitor; B-Cell Lymphoma 2 Protein Inhibitor,,H. Lee Moffitt Cancer Center and Research Institute,National Comprehensive Cancer Network; AstraZeneca,100,2025-06-05,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT07030400
NCT07285668,Phase I Study of Prophylactic TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies,Not Applicable,Not yet recruiting,Interventional,Hematologic Malignancies,Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells,,"University of Wisconsin, Madison",,38,2026-01-05,2031-01-05,United States,No,https://clinicaltrials.gov/study/NCT07285668
